The Lambert Initiative for Cannabinoid Therapeutics
Advancing cannabinoid-based treatments to alleviate human suffering
The Lambert initiative is an Australian first in the field of medicinal cannabinoids.
It will explore the potential of compounds derived from the cannabis plant (cannabinoids) in treating a range of diseases. Our approach will involve medicinal chemistry, cellular and preclinical research, early human testing and clinical trials in patients.
The Lambert Initiative will also translate research outcomes into practice by providing training to health professionals and engaging consumer organisations and media to educate the public and transform current policy.
Our overall aim is to optimise and introduce safe and effective cannabinoid therapeutics into mainstream medicine in Australia and beyond.
We will target a range of conditions including paediatric epilepsy, cancer, chronic pain, obesity, dementia and mental health disorders.
A promising major advance for cannabis-based medications.
Three-year-old Katelyn Lambert has Dravet Syndrome, a rare and extreme form of epilepsy. Without any new treatments Katelyn faces a lifetime of seizures and moderate to severe mental retardation.
On the surface it appears that Professor Iain McGregor (PhD (Psych) '92), an international leader in cannabinoid research, and Mr Barry Lambert, founder of Count Financial, don't have much in common.